Get the Stockscreener App
69.53
4.58%
-3.34
After Hours:
69.52
-0.01
-0.01%
Corcept Therapeutics Inc stock is traded at $69.53, with a volume of 697.91K.
It is down -4.58% in the last 24 hours and down -3.09% over the past month.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
See More
Previous Close:
$72.87
Open:
$72.87
24h Volume:
697.91K
Relative Volume:
0.69
Market Cap:
$7.33B
Revenue:
$628.56M
Net Income/Loss:
$141.82M
P/E Ratio:
55.18
EPS:
1.26
Net Cash Flow:
$142.60M
1W Performance:
-2.39%
1M Performance:
-3.09%
6M Performance:
+24.14%
1Y Performance:
+82.45%
1-Day Range:
$69.48
$73.82
1-Week Range:
$69.48
$74.79
52-Week Range:
$37.82
$117.33
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650.688.8803
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
69.53 | 7.68B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.21 | 101.15B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.14 | 61.07B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.59 | 59.35B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.83 | 46.29B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.27 | 35.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-23 | Upgrade | Truist | Hold → Buy |
| Apr-11-23 | Initiated | SVB Securities | Market Perform |
| Apr-04-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-22 | Downgrade | Truist | Buy → Hold |
| Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
| Jun-27-22 | Resumed | Canaccord Genuity | Buy |
| Feb-02-22 | Initiated | Canaccord Genuity | Buy |
| Jan-28-22 | Initiated | Truist | Buy |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-19 | Initiated | Jefferies | Buy |
| Sep-06-19 | Initiated | H.C. Wainwright | Buy |
| Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-10-18 | Reiterated | Stifel | Hold |
| May-31-18 | Downgrade | Stifel | Buy → Hold |
| Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Aug-31-17 | Initiated | Stifel | Buy |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-21-15 | Initiated | FBR Capital | Outperform |
| Jan-13-14 | Downgrade | Stifel | Buy → Hold |
| Aug-09-13 | Downgrade | Janney | Buy → Neutral |
| Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
| Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
Corcept Can't Escape Teva's Mifepristone Antitrust Suit - Law360
Corcept Fails to Escape Antitrust Claims in Drug Kickback Case - Bloomberg Law News
Drugmaker Corcept must face Teva lawsuit over mifepristone 'monopoly' for rare disorder - Reuters
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Holdings in Corcept Therapeutics Incorporated $CORT - MarketBeat
Empowered Funds LLC Purchases 81,297 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
United Services Automobile Association Purchases Shares of 6,069 Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept’s (CORT) Multibagger Momentum Builds on Relacorilant and Expanding Commercial Footprint - MSN
Acadian Asset Management LLC Increases Stock Holdings in Corcept Therapeutics Incorporated $CORT - MarketBeat
Alliancebernstein L.P. Lowers Stock Holdings in Corcept Therapeutics Incorporated $CORT - MarketBeat
Intech Investment Management LLC Grows Stock Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics Incorporated $CORT Stake Lifted by Jones Financial Companies Lllp - MarketBeat
Corcept Therapeutics Incorporated $CORT Shares Acquired by Bayforest Capital Ltd - MarketBeat
Iron Gate Global Advisors LLC Makes New $400,000 Investment in Corcept Therapeutics Incorporated $CORT - MarketBeat
Coppell Advisory Solutions LLC Buys 14,590 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) Given New $140.00 Price Target at Canaccord Genuity Group - MarketBeat
AQR Capital Management LLC Sells 23,561 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
Scientech Research LLC Has $1.62 Million Stock Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
Analysts Set Corcept Therapeutics Incorporated (NASDAQ:CORT) Price Target at $134.50 - MarketBeat
FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer - sharewise.com
FDA Accepts NDA for Relacorilant in Platinum-Resistant Ovarian Cancer - Targeted Oncology
Central serous chorioretinopathy Pipeline Analysis & Clinical - openPR.com
Central serous chorioretinopathy Pipeline Analysis & Clinical Trials, 2025, DelveInsight | Targeted Therapy Technologies, Corcept Therapeutics, Bayer, and others - Barchart.com
Jacobs Levy Equity Management Inc. Decreases Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
FDA accepts Corcept’s new drug application for ovarian cancer treatment - Investing.com
Corcept's ovarian cancer treatment under FDA review (CORT) - Seeking Alpha
Corcept Therapeutics Says FDA Accepts NDA on Relacorilant for Treating Ovarian Cancer - MarketScreener
Fda reviews Corcept's nda for relacorilant in drug-resistant ovarian cancer - MarketScreener
FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer - Business Wire
Checkpoint Capital L.P. Acquires Shares of 5,000 Corcept Therapeutics Incorporated $CORT - MarketBeat
Published on: 2025-09-08 19:18:57 - beatles.ru
Predicting Corcept Therapeutics Incorporated trend using moving averages2025 Price Momentum & Fast Exit Strategy with Risk Control - Newser
Canaccord Genuity Maintains a Buy on Corcept Therapeutics (CORT), Retains a $137 PT - MSN
Is Corcept Therapeutics Incorporated a good ESG investmentJuly 2025 Action & Entry Point Confirmation Alerts - خودرو بانک
Published on: 2025-09-06 00:29:23 - خودرو بانک
Ieq Capital LLC Buys 7,844 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
Can Corcept Therapeutics Incorporated weather a recession2025 Trade Ideas & Free Safe Capital Growth Stock Tips - خودرو بانک
Corcept Therapeutics Incorporated stock retracement – recovery analysisQuarterly Profit Report & AI Forecasted Entry and Exit Points - Newser
predicting corcept therapeutics incorporated trend using moving averagesJuly 2025 Weekly Recap & Real-Time Chart Pattern Alerts - Newser
Can Corcept Therapeutics Incorporated hit a new high this monthJuly 2025 Short Interest & Safe Capital Allocation Plans - Newser
Is it time to cut losses on Corcept Therapeutics IncorporatedInsider Buying & Safe Capital Allocation Plans - Newser
Key resistance and support levels for Corcept Therapeutics IncorporatedDollar Strength & Reliable Intraday Trade Alerts - Newser
Assessing Insider Selling at Corcept Therapeutics: Strategic and Market Implications - AInvest
Corcept therapeutics CEO Belanoff sells $2.8m in shares By Investing.com - Investing.com Canada
Raymond James Financial Inc. Has $8.90 Million Stake in Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics officer Maduck sells $1.4m in shares By Investing.com - Investing.com South Africa
Corcept Therapeutics officer Maduck sells $1.4m in shares - Investing.com India
Corcept therapeutics exec Guyer sells $1.4m in shares By Investing.com - Investing.com Canada
Lyon of Corcept Therapeutics sells $351k in shares By Investing.com - Investing.com Canada
Corcept therapeutics exec Guyer sells $1.4m in shares - Investing.com India
Corcept therapeutics CEO Belanoff sells $2.8m in shares - Investing.com
Corcept Therapeutics Inc Stock (CORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.33%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):